Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

Core Insights - Olema Pharmaceuticals has appointed Shawnte M. Mitchell as Chief Legal Officer and Corporate Secretary, bringing extensive experience in the biotechnology industry [1][2] - The company is focused on advancing its late-stage palazestrant programs and OP-3136 KAT6 program through clinical development [2][3] - Olema is committed to transforming the standard of care for breast cancer patients with a pipeline of novel therapies [3] Company Overview - Olema Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted therapies for breast cancer and other conditions [1][3] - The lead product candidate, palazestrant (OP-1250), is currently in a Phase 3 clinical trial called OPERA-01, and the company is also developing a potent KAT6 inhibitor (OP-3136) [3] Leadership Background - Shawnte M. Mitchell has 20 years of experience in the healthcare and life sciences sectors, previously serving as Chief Legal Officer at Genomatica and holding senior legal positions at Zogenix and Aptevo Therapeutics [2] - Ms. Mitchell's expertise includes regulatory, commercial, intellectual property, and business development matters, which will support Olema's strategic priorities [2]